TY - JOUR
T1 - Epigenetic reprogramming in breast cancer
T2 - From new targets to new therapies
AU - Katz, Tiffany A.
AU - Huang, Yi
AU - Davidson, Nancy E.
AU - Jankowitz, Rachel C.
N1 - Publisher Copyright:
© 2014 Informa UK, Ltd.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among women in the United States. Recently, interest has grown in the role of epigenetics in breast cancer development and progression. Epigenetic changes such as DNA methylation, histone modifications, and abnormal expression of non-coding RNAs emerged as novel biomarkers in breast cancer diagnosis, therapy, and prevention. This review focuses on the most recent mechanistic findings underlying epigenetic changes in breast cancer development and their role as predictors of breast cancer risk. The rapid progress in our understanding of epigenetic findings in breast cancer has opened new avenues for potential therapeutic approaches via identification of epigenetic targets. We highlight the development of novel epigenetically targeted drugs, relevant clinical trials in breast cancer patients, and recent approaches combining epigenetic agents with chemotherapy and/or endocrine therapy that may incrementally improve long-term outcomes in appropriately selected breast cancer patients. Biomarkers of response are needed, however, to identify patient subsets that are most likely to benefit from epigenetic treatment strategies.
AB - Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among women in the United States. Recently, interest has grown in the role of epigenetics in breast cancer development and progression. Epigenetic changes such as DNA methylation, histone modifications, and abnormal expression of non-coding RNAs emerged as novel biomarkers in breast cancer diagnosis, therapy, and prevention. This review focuses on the most recent mechanistic findings underlying epigenetic changes in breast cancer development and their role as predictors of breast cancer risk. The rapid progress in our understanding of epigenetic findings in breast cancer has opened new avenues for potential therapeutic approaches via identification of epigenetic targets. We highlight the development of novel epigenetically targeted drugs, relevant clinical trials in breast cancer patients, and recent approaches combining epigenetic agents with chemotherapy and/or endocrine therapy that may incrementally improve long-term outcomes in appropriately selected breast cancer patients. Biomarkers of response are needed, however, to identify patient subsets that are most likely to benefit from epigenetic treatment strategies.
KW - Biomarkers
KW - Breast cancer
KW - Combination therapy
KW - DNA methylation
KW - DNA methyltransferase inhibitor
KW - Epigenetic
KW - Histone deacetylase inhibitor
KW - Histone demethylase
KW - Post-translational modification
UR - http://www.scopus.com/inward/record.url?scp=84907052081&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907052081&partnerID=8YFLogxK
U2 - 10.3109/07853890.2014.923740
DO - 10.3109/07853890.2014.923740
M3 - Review article
C2 - 25058177
AN - SCOPUS:84907052081
VL - 46
SP - 397
EP - 408
JO - Annales medicinae experimentalis et biologiae Fenniae
JF - Annales medicinae experimentalis et biologiae Fenniae
SN - 0785-3890
IS - 6
ER -